Medical AI

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

MiniMed and Abbott are partnering on a dual glucose-ketone sensor, a move that could shift diabetes care from crisis management to proactive DKA prevention.

A new report shows California's self-insured employers face a puzzling trend: workers' comp claims are at a 5-year low, yet costs are surging. Why?

Nephrodite's implantable dialysis system just entered a key FDA program, signaling a major shift in treating kidney failure. Is freedom from the dialysis chair finally in sight?

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

FDA clearance for Pulmera's CBeam platform could democratize surgery by turning standard 2D X-ray machines into advanced 3D imagers, slashing costs.

With a fresh $31M, Advanced NanoTherapies is advancing a first-of-its-kind dual-drug nanoparticle balloon, a technology poised to disrupt the market.

With dual FDA clearances secured, Rhythm AI appoints serial acquirer Mike Dineen as CEO, signaling a strategic pivot from innovation to market conquest.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

A pivotal trial completes enrollment at a record pace while the AMA lays the groundwork for billing. ShiraTronics is rewriting the medtech playbook.

A fivefold increase in one year, THINK Surgical’s miniature robot is reshaping orthopedics with its unique open platform and powerful industry partnerships.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

With new funding from Bregal Sagemount, LSPedia is set to advance its AI tools, moving beyond compliance to build a smarter, safer pharma supply chain.

Following its X3D acquisition, Catalyst MedTech unveils an expanded portfolio and a new strategy to tackle aging equipment and modernize nuclear medicine.

ValGenesis's upcoming event explores AI's pivotal role in pharma validation, charting a course from digital systems to intelligent, compliant operations.

DePuy Synthes acquires novel radiofrequency tracking to move beyond the line-of-sight limits and invasive pins of current robotic joint surgery systems.